Kirchner Group Advises Investor in $230M Financing in the BioTech Sector

14 January 2021 – Kirchner Group is pleased to announce that it acted as an advisor on due diligence to the Alaska Permanent Fund in the recently announced Tessera Therapeutics $230M Series B financing.

According to the announcement Tessera Therapeutics has developed a new technology that has the ability to write therapeutic instructions into the genome to treat diseases at their source. The company will use the latest round of funding to accelerate research and development in the company’s Gene Writing technologies, expand its team, and establish manufacturing and automation capabilities critical for its platform and programs. This investment will accelerate the company’s ability to position multiple therapeutic programs for clinical development.

“It is incredibly exciting to assist investors who are looking at investing in game changing technologies like Tessera,” stated Blair Kirchner of Kirchner Group. “Our ability to complement diligence with deep technical and scientific expertise has been one of our trademarks over the last 35 years.”

Kirchner Group is also proud to note their previous similar roles in the Sana Biotechnology, Inc.,  Denali Therapeutics (NASDAQ: DNLI), Juno Therapeutics (acquired by Celgene for approx. $9B) and Indigo Agriculture financings.

[k]

Kirchner Group

Kirchner Group was founded in 1985 as a boutique advisory firm and today operates various subsidiaries, providing advisory services (M&A, assessments, diligence) and operational support (interim management, workouts, turnarounds) as well as asset management (dedicated, portfolio optimization) – all leveraging a proprietary approach that dovetails domain and process expertise.

Throughout the decades Kirchner Group has been internationally recognized for its unique business model centered around creating value while promoting values: “earning while returning”. The firm has also established a reputation for building and rebuilding important business and social paradigms based on its deep entrepreneurial orientation.

Kirchner Group’s clients and partners include early stage to mid-market companies, venture capital and private equity firms as well as family offices and some of the world’s largest insurance companies, commercial banks and institutional investors. www.kirchnergroup.com

Blair Kirchner | Managing Director & Co-Head of Impact Activities |Kirchner Group | bgkirchner@kirchnergroup.com